Functional genetic variants of DNA repair genes may alter the host DNA repair capacity, and thus influence efficiency of therapies. We genotyped eight potentially functional single nucleotide polymorphisms (SNPs) in genes (i.e. ERCC1, XPA, XPC, XPD and XPG) involved in the nucleotide excision repair (NER) pathway in 496 Japanese gastric cancer patients, and assessed overall survival and recurrence-free survival. The combined effects of risk genotypes of these eight SNPs in Japanese patients were further replicated in 356 North-American gastric cancer patients. In Japanese patients, we found that the XPC rs2228000 TT genotype was associated with shorter overall survival [hazards ratio (HR) = 1.75, 95% confidence interval (95% CI) = 1.07-2.86] and recurrence-free survival (HR = 2.17, 95% CI = 1.19-3.95), compared with CC/CT genotypes, and the XPG rs17655 CC genotype was associated with shorter overall survival (HR = 1.60, 95% CI = 1.08-2.36), compared with GG/CG genotypes. The number of observed risk genotypes in the combined analysis was associated with shorter overall survival and recurrence-free survival in a dose-response manner (P trend = 0.006 and P trend < 0.000) in Japanese patients; specifically, compared with those with ≤1 risk genotypes, those with ≥2 risk genotypes showed markedly shorter overall survival (HR = 1.79, 95% CI = 1.18-2.70) and recurrencefree survival (HR = 2.80, 95% CI = 1.66-4.73). The association between ≥2 risk genotypes and shorter overall survival was not significant (HR = 1.26, 95% CI = 0.82-1.94) in North-American patients, but the trends were similar in these two groups of patients. These data show that functional SNPs in NER core genes may impact survival in Japanese gastric cancer patients.
Introduction
Gastric cancer is the fourth most common cancer in the world and the third leading cause of cancer deaths in men and the fifth among women, with ~989 600 new cases and 738 000 deaths every year (1) .
The highest incident rate is in Eastern Asia, Eastern Europe and South America. To date, for gastric cancer patients, although remarkable achievement has been made on surgery-based comprehensive treatment strategies, the survival remains poor. Moreover, it is not uncommon that patients with the same tumor, node, and metastasis (TNM) stage and the same treatment may have various outcomes. Gastric carcinogenesis and progression are of a complicated process influenced by both genetic and epigenetic factors (2) . In recent decades, studies have found that genetic variations play roles in the development and progression of gastric cancer (3) . Therefore, discovery of these biomarkers would be helpful in improving early diagnosis, screening of high-risk individuals, predicting clinical outcome and personalizing therapy and patient care (4) . Genetic polymorphisms are the most commonly investigated type of genetic variation that may influence patients' clinical outcomes (5, 6) . The goal of this study is to identify single nucleotide polymorphisms (SNPs) associated with clinical progression and survival of gastric cancer in Japanese patients.
The DNA repair system plays a vital role in maintaining the stability of cellular functions and genomic integrity through the reversal of the damaged DNA induced by various factors, including therapeutic agents; therefore, the host DNA repair capacity (DRC) may contribute to cancer patient outcomes (7) . Among the well-known DNA repair pathways, the nucleotide excision repair (NER) pathway is one of the major important mechanisms that remove DNA bulky lesions or interstrand adducts induced by exogenous and/or endogenous factors. If left unrepaired, these lesions will interfere with base pairing and obstruct replication and transcription (8) . Several critical genes participate in the NER process and have functions to cope with different types of DNA damage and to maintain genomic integrity (9) . In the NER process, the XPC-HR23B complex first detects the DNA damage site and then recruits the transcription factor IIH (including two helicase: ERCC3/XPB and ERCC2/XPD) to open the DNA strands around the site of the lesion (10, 11) . Subsequently, a multiprotein factor composed of XPA and the single-strand DNA-binding protein replication protein A monitors DNA binding and unwinding to verify the damage-specific localization of repair complexes or to assure the correct three dimensional assembly (12) . Thereafter, the open DNA complex creates the substrate for cleavage by two structure-specific end nucleases ERCC1-XPF (13) and XPG (14) .
Germ-line mutations in the core NER repair genes (e.g. ERCC1, XPA, XPB, XPC, XPD, XPE, XPF and XPG) may alter their protein functions and thus may affect the host DRC. Several studies have demonstrated that some non-synonymous SNPs in the NER core genes may affect outcomes for cancer patients. For example, the XPC rs2228000 is associated with outcomes in Chinese patients with stages III-IV non-small cell lung cancer treated by platinum-based chemotherapy without surgical operation (15) , and the XPC rs2228001 variant genotypes are associated with a shorter time to progression in non-small cell lung cancer patients who were former smokers (16) . Likewise, XPD rs13181 and rs1799793 SNPs have been shown to be prognostic predictors for patients with osteosarcoma (17), colorectal cancer (18) and oral cancer (19) . In addition, the XPG rs17655 is an independent prognostic factor for the clinical course of melanoma (20) . Besides these potential functional SNPs, there are two other SNPs located at the 3′ untranslated region of ERCC1 rs3212986 (C8092A) and the 5′ untranslated regions of XPA rs1800975 (G23A) that are well documented and correlated with the DRC phenotype (21) . To date, although many studies have investigated the roles of functional polymorphisms in the NER pathway genes on clinical outcomes of cancer patients, the reported findings are conflicting, and the significance of the identified associations is still largely unclear, and only a few studies have investigated prognostic importance of these SNPs in gastric cancer patients. In this study, we hypothesized that the common, functional NER SNPs are associated with gastric cancer prognosis. To test this hypothesis, we evaluated the impact of eight functional variants in the NER core genes on clinical outcomes among 496 Japanese patients and 356 North-American patients with gastric cancer. Because the defective DRC phenotypes in the xeroderma pigmentosum syndrome fit a recessive genetic model (22) , in which the disease phenotype occurs only when patients carried two mutated alleles of the xeroderma pigmentosum genes; therefore, for all analyses, we explored the genotype-risk associations by using a recessive genetic model, as we used previously (23) .
Materials and methods

Study subjects
This study protocol was approved by the ethical committee and had an executed material transfer agreement (MTA) between the St Luke's International Hospital and The University of Texas MD Anderson Cancer Center. This analysis was conducted under an MD Anderson Cancer Center protocol approved by the Institutional Review Board.
Japanese patients were sequentially accrued from those with newly diagnosed, underwent surgical resection and histologically confirmed gastric cancer, regardless of age, sex or tumor stage, at Department of Gastroenterological Surgery at St Luke's International Hospital in Japan between 1999 and 2009. Formalin-fixed and paraffin-embedded blocks of normal tissues clearly separated from tumors of these patients were collected from the Department of Pathology of the Hospital. The validation of major findings was performed in North-American patients who were also accrued sequentially from those with newly diagnosed and histologically confirmed gastric cancer, regardless of age, sex or tumor stage, at MD Anderson Cancer Center between 1990 and 2012. Each patient donated 10 ml of the whole blood drawn into a heparinized tube for genetic testing. All the patients had relevant information on demographic and clinical characteristics, including the pathological stage, histological type (intestinal or diffuse), differential grade, at the presentation of the index tumor and treatment information, which were obtained from review of the medical records. The clinical outcomes included overall survival and recurrence-free survival.
Patients were followed up during the course of treatment and post-treatment with scheduled clinical and radiographic examinations. Patients who lost in contact or still alive at the last follow-up time were considered censored in overall survival analyses. 'Recurrence disease' was defined as appearance of a new lesion that had radiographic or histological evidence of tumor reappearance or development as documented in the medical record, and patients who lost in contact or had no recurrence disease at the last follow-up time were considered censored in recurrence-free survival analyses. However, due to the lack of information about recurrence disease on MD Anderson patients, we were only able to perform the combined analysis for genotype effects for the validation of overall survival. His), but none was identified in XPB, XPE and XPF. In addition of these six SNPs, another two common regulatory SNPs, ERCC1 rs3212986 (C8092A) and XPA rs1800975 (G23A), which was also reported to be correlated with the DRC (21), had been included in this study.
Selection of candidate gene and SNPs
Genotyping
Genomic DNA was extracted from formalin-fixed paraffin-embedded normal tissue samples and buffy coat fraction of the blood sample, using the QIAamp formalin-fixed paraffin-embedded Tissue Kit and Blood Mini Kit (Qiagen, Valencia, CA), respectively, according to the manufacturer's handbook instruction. Extracted DNA concentrations were determined by spectrophotometric measurement of absorbance at 260 nm, and the purities were calculated by A260/A280 ratio using a Nanodrop ND-1000 spectrophotometer (Thermo Scientific, Rockford, IL). Genotypes of the eight selected SNPs (ERCC1 rs3212986, XPA rs1800975, XPC rs1870134, XPC rs2228000, XPC rs2228001, XPD rs13181, XPD 1799793 and XPG rs17655) were performed using the TaqMan methodology in 384-well plates and read with the Sequence Detection Software on the ABI Prism 7900 instrument according to the manufacturer's instructions (Applied Biosystems, Foster City, CA). The primers used in genotyping for these SNPs were:
Each 384-well plate had four negative controls, one positive control and eight repeated samples. PCR reactions were done under the following conditions: 50°C for 2 min, 95°C for 10 min and then 95°C for 15 s and 60°C for 1 min for 40 cycles. For all genotypes, the assay success rate was >99% and the results of repeated samples were 100% concordant.
Statistical analysis
The goodness-of-fit χ 2 test was applied to calculate the Hardy-Weinberg equilibrium of genotype distribution. The Kaplan-Meier method was used to visualize overall survival and recurrence-free survival by genotype groups. Also, the median time of overall survival and recurrence-free survival was calculated, and the log-rank test was applied to test for differences in the survival time among the patients. Univariate and multivariate Cox proportional hazards models were performed to calculate hazards ratios (HRs) and 95% confidence intervals (CIs) of each genotype to estimate its effect on survival with or without adjustment for confounding factors. Considering the survival of cancer patients may be influenced by unknown confounders, all the tumor-related clinical and pathological characteristics, including sex, age, histological type, tumor grade, stage and chemotherapy were put into the same Cox model in subsequent analyses. In the analyses of combined genotypes, we combined all putative risk genotypes (those associated with adjusted HR > 1.0 in a recessive genetic model) of each SNP into a new variable of genotype risk score to assess the joint effect of these risk genotypes (i.e. ERCC1 rs3212986 TT, XPA rs1800975 AA, XPC rs2228000 TT, XPC rs2228001 CC, XPD rs13181 GG, XPD rs1799793 AA and XPG rs17655 CC) on patients' prognosis. Further stratified analysis and heterogeneity test were applied to assess heterogeneity across stratified groups. All analyses of genetic effects were performed under a recessive disease model as observed in xeroderma pigmentosum patients (22) . All statistical tests were two-sided, with a P value of 0.05 considered significant, and all analyses were performed using SAS software version 9.3 (SAS Institute, Cary, NC).
Results
Associations between clinicopathological characteristics and overall survival
Of 501 Japanese gastric cancer patients accrued in this study, two patients were excluded due to lack of tissue samples or lack of the follow-up information, and additional three patients were excluded due to lack of pathological TNM stage. As a result, 496 cases were included in the final analysis. At the last follow-up (December 2012), 110 patients died, with a median overall survival of 56.3 months. Demographic variables, clinical characteristics and risk factors for the overall cohort of the patients are presented in Table I . There were more men (306, 61.69%) than women (190, 38.31%), with a median age of 65 years ranging between 23 and 94 years, and older patients (>65 years) had a significantly shorter overall survival time, compared with younger ones (median, 50.6 months versus 60.8 months; logrank P = 0.003).
Clinical pathological characteristics, including histological type, poorer differentiation, T/N/M and TNM stages and chemotherapy were significantly associated with overall survival time (log-rank P < 0.05 for all). When all of these variables were included in a Cox proportional hazards regression model for adjustment, the adjusted HRs for >65 years of age (adjusted HR = 1. Table II shows genotype distributions of the eight SNPs, the results from the Kaplan-Meier survival analysis and univariate/multivariate Cox proportional hazards regression analyses of the associations between the eight SNPs and overall survival in gastric cancer patients. The distribution of observed genotypes in the patients agreed with those estimated from the Hardy-Weinberg equilibrium (P = 0.870 for ERCC1 rs3212986, P = 0.054 for XPC rs2228000, P = 0.267 for XPC rs2228001, P = 0.067 for XPD rs13181, P = 0.880 for XPD rs1799793 and P = 0.074 for XPG rs17655, except for P = 0.018 for XPA rs1800975 and P = 0.008 for XPC rs1870134). As shown in Table  II , the variant XPG rs17655 CC genotype was associated with significantly shorter overall survival time, compared with XPG rs17655 GG/ CG genotypes (median, 53.4 months versus 56.9 months, log-rank P = 0.014), but no significant difference in overall survival was observed for other SNPs (log-rank P > 0.05 for all). In the univariate Cox proportional hazards regression analyses, a significant association was observed between the XPG rs17655 CC genotype and poor overall survival (HR = 1.61, 95% CI = 1.10-2.35), compared with GG/CG genotypes. In the multivariate Cox model, the XPC rs2228000 TT genotype was significantly associated with worse overall survival (adjusted HR = 1.75, 95% CI = 1.07-2.86), compared with the CT/CC genotypes, and the XPG rs17655 CC genotype remained statistically significantly associated with poorer overall survival (adjusted HR = 1.60, 95% CI = 1.08-2.36), compared with the GG/CG genotypes. For the other six SNPs, we did not find any significant association with overall survival under recessive genetic models (Table II) . However, we found that the XPC rs2228000 TT genotype was associated with an increased risk of shorter recurrencefree survival in 434 Japanese patients with stages I-III gastric cancer (adjusted HR = 2.17, 95% CI = 1.19-3.95), compared with the CT/ CC genotypes, and that the association between the XPG rs17655 CC genotype and recurrence-free survival was marginally significant (adjusted HR = 1.59, 95% CI = 0.96-2.63) (Table IV) .
Association between SNPs in NER core genes and survival
Associations between combined genetic risk factors and survival of gastric cancer
We performed the association analyses between number of risk genotypes (risk genotype score) and overall survival in both Japanese and North-American patients. As shown in Table III , in Japanese patients, the frequencies of patients with 0, 1, 2, 3 and 4 risk genotypes were 161, 233, 83, 16 and 3, respectively; no patient had five or more risk genotypes. It was apparent that an increasing number of risk genotypes was markedly associated with an increased risk of death and a decreased median overall survival time, compared with those without any risk genotypes (P trend = 0.006 and log-rank P = 0.002). When we dichotomized the score, compared with one or less risk genotypes, two or more risk genotypes were significantly associated with a shorter overall survival time (median, 49.6 months versus 57.6 months, log-rank P < 0.001) and a marginally shorter overall survival in North-American patients (median, 12.9 months versus 16.9 months, log-rank P = 0.092) (Figure 1) . Consistently, in the multivariate Cox proportional hazards model, compared with 0-1 risk genotypes, two or more risk genotypes were markedly associated with an increased risk of death (adjusted HR =1.79, 95% CI = 1.18-2.70) in Japanese patients but a non-significantly increased risk of death (adjusted HR = 1.26, 95% CI = 0.82-1.94) in North-American patients. Further analyses showed that there was no heterogeneity of HRs and 95% CIs between Japanese and North-American patients, and the combined effect remained significant (HR = 1.45, 95% CI = 1.00-1.90) (Figure 1 ). Further stratified analyses showed that patients carrying two or more risk genotypes would suffer a shorter median overall survival, particularly in those who were male or older (>65 years), had diffuse tumor, well/poor tumor differentiation, T1-2/T3-4 stage, N0/N1-3 stage, M0 stage, III-IV TNM stage or had no chemotherapy (logrank P < 0.05). Consistently, in the multivariate Cox model, greater risks of death were more evident for males (adjusted HR = 1.90, 95% CI = 1.13-3.18), older subjects (adjusted HR = 1.92, 95% CI = 1.15-3.23), N1-3 stage (adjusted HR = 2.01, 95% CI = 1.25-3.21), M0 stage (adjusted HR = 3.02, 95% CI = 1.83-4.99) and no chemotherapy (adjusted HR = 2.13,95% CI = 1.2-3.68). However, there were no significant differences in these stratum HRs in the stratified groups (P het > 0.05), except for between the M0 and M1 groups (P heterogeneity = 0.040) (Supplementary Table S1 , available at Carcinogenesis Online). As shown in Table IV , in the 434 patients with stages I-III gastric cancer, an increasing number of risk genotypes was markedly associated with an increased risk of disease recurrence and a decreased median recurrence-free survival time (P trend = 0.000 and log-rank P < 0.000). Moreover, compared with one or less risk genotypes, two or more risk genotypes were significantly associated with a shorter recurrencefree survival time (median, 52.8 months versus 60.2 months, log-rank P < 0.000) and a markedly increased risk of recurrence (adjusted HR = 2.80, 95% CI = 1.66-4.73). Further stratified analyses showed (Supplementary Table S2 , available at Carcinogenesis Online) that in Finally, we investigated the association between the number of risk genotypes and patients' overall survival and recurrencefree survival in those patients who had chemotherapy. As shown in Supplementary Table S3, available at Carcinogenesis Online, there were 114 Japanese and 289 North-American patients who received chemotherapy. Although careers of the two or more risk genotypes exhibited a shorter median overall survival time in both patient populations, compared with those one or less risk genotypes (28.9 months versus 33.9 months in Japanese patients and 12.0 months versus 15.3 months in North-American patients, respectively), no significant difference was found. However, among Japanese patients who received chemotherapy, two or more risk genotypes were significantly associated with a shorter recurrence-free survival time (21.9 months versus 40.9 months, log-rank P = 0.018), compared with one or less risk genotypes, but the association was no longer significant in the multivariate Cox model (adjusted HR = 2.39, 95% CI = 0.84-6.80) (Supplementary Table S2 , available at Carcinogenesis Online).
Discussion
In this study, we investigated the associations between eight functional SNPs of the NER pathway core gene and survival in Japanese and North-American patients with gastric cancer. In Japanese patients, we found that the XPC rs2228000 SNP was associated with an increased risk of poor overall survival and recurrence-free survival, and the XPG rs17655 SNP exhibited a significant association with a shorter overall survival. In these Japanese patients, we also found that the number of combined risk genotypes of these NER core genes was associated with a poor gastric cancer overall survival and recurrence-free survival in a dose-response manner, and the dichotomized number of combined risk genotypes was significantly associated with a poor prognosis; these genetic effects tended to be present in North-American patients, although to a less extent.
The NER process is an important mechanism that maintains genomic integrity in normal cells as well as tumor cells, and the alteration in the NER capacity may either increase DNA mutation frequencies as a result of unrepaired damaged DNA. Therefore, genetic variants of NER pathway genes may alter patients' response to the therapies (chemotherapy/radiotherapy) and have an impact on malignant progression and recurrence, leading to a poorer survival. Moreover, it is well established that DRC is associated with clinical outcomes in cancer patients (7, 24) , and there is evidence that genetic variants in the DNA repair pathway genes may modulate the DRC phenotype and affect prognosis of patients with various cancers in response to chemotherapies (5, 25, 26) . Thus, it is biologically plausible that genetic variants in NER genes may influence clinical outcomes in cancer patients.
It is known that the XPC participates in recognizing DNA damage and initiating the NER process. XPC rs2228000 is located in the region of the HR23B interaction domain of XPC, and the amino change (Ala to Val) may affect the XPC-HR23B interaction, probably altering the NER capacity (27) . Prior evidence indicated that subjects carrying rs2228000 CT/TT genotypes had a better DRC, compared with those carrying the rs2228000 CC genotype (21, 28) , and a significant association between the rs2228000 SNP and a poorer survival or risk of recurrence was found in oropharynx squamous cell carcinoma (29) and acute myeloid leukemia (30) , a finding consistent with that in this study. These findings indicate that the rs2228000 SNP may play a role in DRC and influence recurrence in cancer patients, but further functional studies are needed to uncover the exact underlying mechanism. XPG encodes an 1186-amino acid protein as an endonuclease that is an indispensable component of the NER pathway and acts as a cofactor for Endonuclease III-like protein 1, in which it facilitates the binding to damaged DNA in base excision repair process (31) involved in another NER genes polymorphisms predict GC survival primary DNA repair pathway known for repair of small DNA modifications caused by alkylation, deamination or oxidation (32) . The rs17655 SNP is the most frequently studied XPG polymorphism located in the XPG C-terminus, which is required for its interaction with other components of the NER pathway, such as XPB, XPD and TFIIH subunits (33) . The rs17655 amino acid change (His to Asp) may influence these protein-protein interactions; however, to our best knowledge, such a potentially functional relevance has not been reported to date. In prior studies, the XPG rs17655 SNP has been reported to contribute to a poorer survival in patients with multiple cancers, including cutaneous melanoma (20) , colorectal carcinoma (26), squamous cell carcinoma of the oropharynx (29) and ovarian cancer (34) . However, inconsistent findings have also been reported in an earlier, relatively smaller sample size study of 288 patients of superficial bladder cancer (35) . Taken together, the XPG rs17655 SNP may be associated with cancer patients' survival, probably by altering host DRC, but the mechanisms underlying these associations remain to be determined. The ERCC1 rs3213986 SNP was reportedly to influence the nonsmall cell lung cancer prognosis regardless of the ERCC1 expression and platinum sensitivity (36) ; however, one study of 300 Chinese nonsmall cell lung cancer patients showed that there was lack of association between ERCC1 rs3212986 SNP and overall survival or efficacy/ toxicity of platinum-based chemotherapy (37) . Furthermore, a recent meta-analysis showed that there was no evidence to support ERCC1 rs3212986 SNP as a prognostic predictor of platinum-based chemotherapy in patients with non-small cell lung cancer (38) . In this study, we did not find a significant association between ERCC1 rs3212986 SNP and survival among gastric cancer patients. XPA is an essential DNA-binding protein in the NER process (39) , and the rs1800975 SNP, which is located on the 5′ untranslated regions of XPA, have been reported to be associated with higher expression levels of XPA mRNA (40) and the DRC phenotype (21, 41) . The XPA rs1800975 SNP was reported to be an independent significant risk factor of death and tumor recurrence among patients with esophageal cancer (42) and ovarian cancer (34), but conflicting result was also reported for squamous cell carcinoma of the oropharynx (29) . In this study, we did not find any significant association between XPA rs1800975 SNP and clinical outcomes in gastric cancer patients. Previous studies have also shown that XPD rs13181 G and rs1799793 A variant genotypes may lead to a low NER capacity, compared with the common genotypes and thus might influence patient outcomes (43, 44) . XPD rs13181 G and rs1799793 A variant genotypes were found to be associated with a significantly poorer survival in Chinese patients with non-small cell lung cancer (45) and North-American patients with gastric cancer (23) . In this study, for both XPD rs13181 and rs1799793, the variant homozygotes were rare (2/496 for rs13181 and 1/496 for rs1799793) in Japanese patients, and no statistical significant result was found in this study, which should be validated in the larger studies in the future.
The cancer survival is complicated and influenced by various factors, including endogenous and exogenous factors. The effect of a single SNP on cancer patients' outcomes, if any, may be limited as one would expect, and the combined effects of multiple SNPs may be more significant (5). More importantly, functional SNPs are the most possibly factors that affect gene function during cancer development and throughout the course of anticancer therapy. Indeed, in this study, we observed that Japanese patients with gastric cancer, who had two or more homozygous risk genotypes of these functional NER SNPs, had a markedly decreased overall survival and recurrence-free survival, compared with those carrying one or less risk genotypes. And we observed associations with a similar trend in North-American patients as well. These findings are biologically plausible, because all these unfavorable variant homozygous genotypes might collectively have a substantial effect on patients' outcomes, probably due to the joint effects of multiple functional SNPs on the host's DRC. It is presumable that subjects who carry more risk genotypes will have a poorer DRC than those who carry fewer or without any. The findings in the further stratified analyses also suggested that for patients who had higher levels of DNA damage-related risks, the two or more risk genotypes were associated with more prominent poor overall survival/recurrence-free survival than one or less risk genotypes. However, we also observed that the effect of two or more risk genotypes on overall survival was more evident in patients without distant metastasis. That may partly explain why the SNPs' effects were not marked in late stage IV gastric cancer patients whose tumor phenotype would be more probably influenced by somatic mutations rather than inherited genetic factors, leading to a poor survival (46) . However, among patients who received chemotherapy, we did not find any significant association between number of risk genotypes and survival in a multivariate Cox model, probably due to a weak effect with a reduced sample size, and larger studies are needed in the further to validate these findings.
Taken together, previous studies and our present observations suggest that, compared with other unknown competing risk factors, a single genetic variant may be insufficient to predict risk of complex cancer survival. Apart from those common potential functional SNPs, other SNPs in genes' introns and promoters that may be regulatory in gene expression should be comprehensively studied for their associations with cancer survival. Therefore, careful consideration is necessary in candidate SNP selection to cover those potential functional, particularly rare but truly critical SNPs in future association and clinical outcome studies as well as further mechanistic studies.
This study has some limitations. First, we were unable to explore the exact mechanisms by which NER core gene SNPs influence gastric cancer survival. Second, we used the reported common, functional SNPs, which did not include all representative SNPs in the entire gene. Some other rare functional SNPs, which could influence survival, may have been missed and need to be investigated in future larger studies. Third, although this study included a relatively large number of gastric patients than previously published studies, due to the limitation of available clinical data, we were not able to evaluate the potential role of the SNPs by different chemotherapies or radiotherapy, because the treatment may cause different types of DNA damage. Finally, although this study included two patient populations with relatively larger sample sizes, the findings in Japanese patients were not truly validated in North-American patients, probably due to the limited number of patients who were available for this study, because gastric cancer is not common in North America. Larger validation studies with multiethnic groups are still needed to confirm our findings.
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